Immune checkpoint inhibitors for nonsmall cell lung cancer treatment

Journal of the Chinese Medical Association

Volumn 80, Issue 1, 2017, Pages 7-14

  Chen, Yuh Min ^a,b,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

adenocarcinoma; checkpoint inhibitor; immunotherapy; lung cancer; lymphocytes

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; IMMUNE CHECKPOINT INHIBITOR; IPILIMUMAB; LIGAND; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED CELL DEATH PROTEIN 1 LIGAND; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; PROGRAMMED DEATH 1 LIGAND 1;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DISEASE MARKER; FOOD AND DRUG ADMINISTRATION; HUMAN; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; REVIEW; SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; CARCINOMA, NON-SMALL-CELL LUNG; CTLA-4 ANTIGEN; HUMANS; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84999791810     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2016.08.005     Document Type: Review

References (66)

1. 1 Wang, B.Y., Huang, J.Y., Cheng, C.Y., Lin, C.H., Ko, J., Liaw, Y.P., Lung cancer and prognosis in Taiwan: a population-based cancer registry. J Thorac Oncol 8 (2013), 1128–1135.
2. 2 Dasanu, C.A., Sethi, N., Ahmed, N., Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther 12 (2012), 923–937.
3. 3 Marincola, F.M., Jaffee, E.M., Hicklin, D.J., Ferrone, S., Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74 (2000), 181–273.
4. 4 Brahmer, J.R., Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol 31 (2013), 1021–1028.
5. 5 Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192 (2000), 1027–1034.
6. 6 Chen, L., Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4 (2004), 336–347.
7. 7 Holt, G.E., Podack, E.R., Raez, L.E., Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy 8 (2011), 43–54.
8. 8 Chen, Y.M., Yang, W.K., Ting, C.C., Tsai, W.Y., Yang, D.M., Whang-Peng, J., et al. Cross regulation by IL-10 and IL-2/IL-12 of the cytolytic activity of lymphocyte from malignant effusion of lung cancer patients. Chest 112 (1997), 960–966.
9. 9 Chen, Y.M., Yang, W.K., Whang-Peng, J., Tsai, W.Y., Hung, Y.M., Yang, D.M., et al. Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor specific CTL from lung cancer patients. J Immunotherapy 20 (1997), 354–364.
10. 10 Chen, Y.M., Yang, W.K., Whang-Peng, J., Kuo, B.I.T., Perng, R.P., Elevation of interleukin-10 levels in malignant pleural effusion. Chest 110 (1996), 433–436.
11. 11 Chen, Y.M., Whang-Peng, J., Yang, W.K., Hung, Y.M., Lin, W.C., Kuo, B.I.T., et al. Low levels of NK cells and related cytokines in pleural effusion. J Chin Med Assoc 58 (1996), 156–162.
12. 12 Chen, Y.M., Yang, W.K., Yang, K.Y., Whang-Peng, J., Tsai, C.M., Perng, R.P., An analysis of cytokine status in the serum and effusions of patients with tuberculous and lung cancer. Lung Cancer 31 (2001), 25–30.
13. 13 Wesselius, L.J., David, L., Wheaton, B.S., Wahl, L.J.M., Sherad, S., Taylor, S.A., Lymphocyte subsets in lung cancer. Chest 91 (1987), 725–729.
14. 14 Woo, E.Y., Yeh, H., Chu, C.S., Schlienger, K., Carroll, R.G., Riley, J.L., et al. Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168 (2002), 4272–4276.
15. 15 Chen, Y.M., Tsai, C.M., Whang-Peng, J., Perng, R.P., Double signal stimulation was required for full recovery of the autologous tumor-killing effect of effusion-associated lymphocytes. Chest 122 (2002), 1421–1427.
16. 16 Chen, Y.M., Tsai, C.M., Perng, R.P., Differential effects of different cytokines on the tumorigenicity and immunogenicity of murine tumors. J Chin Med Assoc 62 (1999), 807–816.
17. 17 Chen, Y.M., Ting, C.C., Whang-Peng, J., Yang, K.Y., Yang, W.K., Tsai, C.M., et al. Restoration of cytotoxic T lymphocytes function in malignant pleural effusion: interleukin-15 versus interleukin-2. J Interferon Cytokine Res 20 (2000), 31–39.
18. 18 Chen, Y.M., Tsai, C.M., Whang-Peng, J., Perng, R.P., IL-7 and IL-12 have different effects in recovery of depressed cellular immunity of malignant pleural effusion compared with tuberculous pleural effusion. J Interferon Cytokine Res 21 (2001), 249–256.
19. 19 Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., et al. Colocalization of inflammatory response with B7–h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med, 4, 2012, 127ra37.
20. 20 Topalian, S.L., Drake, C.G., Pardoll, D.M., Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor immunity. Curr Opin Immunol 24 (2012), 207–212.
21. 21 Schneider, H., Downey, J., Smith, A., Zinselmeyer, B.H., Rush, C., Brewer, J.M., et al. Reversal of the TCR stop signal by CTLA-4. Science 313 (2006), 1972–1975.
22. 22 Riley, J.L., Mao, M., Kobayashi, S., Biery, M., Burchard, J., Cavet, G., et al. Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. Proc Natl Acad Sci USA 99 (2002), 11790–11795.
23. 23 Qureshi, O.S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E.M., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332 (2011), 600–603.
24. 24 Krummel, M.F., Allison, J.P., CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183 (1996), 2533–2540.
25. 25 Waterhouse, P., Penninger, J.M., Timms, E., Wakeham, A., Shahinian, A., Lee, K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270 (1995), 985–988.
26. 26 Gabriel, E.M., Lattime, E.C., Anti-CTL associated antigen 4: are regulatory T cells a target?. Clin Cancer Res 13 (2007), 785–788.
27. 27 Leach, D.R., Krummel, M.F., Allison, J.P., Enhancement of antitumor immunity by CTLA-4 blockade. Science 271 (1996), 1734–1736.
28. 28 van Elsas, A., Hurwitz, A.A., Allison, J.P., Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190 (1999), 355–366.
29. 29 Phan, G.Q., Yang, J.C., Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzentruber, D.J., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100 (2003), 8372–8377.
30. 30 Ribas, A., Camacho, L.H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C.A., Millham, R., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23 (2005), 8968–8977.
31. 31 Hodi, F.S., Butler, M., Oble, D.A., Seiden, M.V., Haluska, F.G., Kruse, A., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105 (2008), 3005–3010.
32. 32 Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
33. 33 Lynch, T.J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 30 (2012), 2046–2054.
34. 34 Wolchok, J.D., Hoos, A., O'Day, S., Weber, J.S., Hamid, O., Lebbe, C., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
35. 35 Miller, A.B., Hoogstraten, B., Staquet, M., Winkler, A., Reporting results of cancer treatment. Cancer 47 (1981), 207–214.
36. 36 Reuben, J.M., Lee, B.N., Li, C., Gomez-Navarro, J., Bozon, V.A., Parker, C.A., et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer 106 (2006), 2437–2444.
37. 37 Pfizer Inc. press release – Pfizer announces discontinuation of phase III clinical trial for patients with advanced melanoma. Available at: http://www.pfizer.com/news/press release/press release detail/pfizer announces discontinuation of phase III clinical trial for patients with advanced melanoma. [Date accessed: 06 Nov 2015].
38. 38 Calabrò, L., Morra, A., Fonsatti, E., Cutaia, O., Amato, G., Giannarelli, D., et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 14 (2013), 1104–1111.
39. 39 Keir, M.E., Liang, S.C., Guleria, I., Latchman, Y.E., Qipo, A., Albacker, L.A., et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203 (2006), 883–895.
40. 40 Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8 (2002), 793–800.
41. 41 Nishimura, H., Nose, M., Hiai, H., Minato, N., Honjo, T., Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11 (1999), 141–151.
42. 42 Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291 (2001), 319–322.
43. 43 Fanoni, D., Tavecchio, S., Recalcati, S., Balice, Y., Venegoni, L., Fiorani, R., et al. New monoclonal antibodies against B-cell antigens: possible new strategies for diagnosis of primary cutaneous B-cell lymphomas. Immunol Lett 134 (2011), 157–160.
44. 44 Rizvi, N.A., Mazieres, J., Planchard, D., Stinchcombe, T.E., Dy, G.K., Antonia, S.J., et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16 (2015), 257–265.
45. 45 Gettinger, S.N., Horn, L., Gandhi, L., Spigel, D.R., Antonia, S.J., Rizvi, N.A., et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33 (2015), 2004–2012.
46. 46 Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 (2015), 123–135.
47. 47 Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New Engl J Med 373 (2015), 1627–1639.
48. 48 Gettinger, S.N., Hellmann, M.D., Shepherd, F.A., Antonia, S.J., Brahmer, J.R., Chow, L.Q.M., et al. First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. J Clin Oncol, 33(Suppl), 2015 abstract 8025.
49. 49 Antonia, S.J., Brahmer, J.R., Gettinger, S.N., Chow, L.Q.M., Juergens, R.A., Shepherd, F.A., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 32(Suppl), 2014 abstract 8113.
50. 50 Rizvi, N.A., Chow, L.Q.M., Borghaei, H., Shen, Y., Harbison, C., Alaparthy, S., et al. Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC. J Clin Oncol, 32(Suppl), 2014 abstract 8022.
51. 51 Antonia, S.J., Gettinger, S.N., Chow, L.Q.M., Juergens, R.A., Borghaei, H., Shen, Y., et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. J Clin Oncol, 32(Suppl), 2014 abstract 8023.
52. 52 Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., et al. Pembrolizumab for the treatment of non-small-cell lung cancer. New Engl J Med 372 (2015), 2018–2028.
53. 53 FDA. Approved drugs. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465650.htm. [Date accessed: 06 Nov 2015].
54. 54 Papadimitrakopoulou, V., Patnaik, A., Borghaei, H., Stevenson, J., Gandhi, L., Gubens, M.A., et al. Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small-cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. J Clin Oncol, 33(Suppl), 2015 abstract 8031.
55. 55 Patnaik, A., Socinski, M.A., Gubens, M.A., Gandhi, L., Stevenson, J., Bachman, R.D., et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small-cell lung cancer (NSCLC): KEYNOTE-021 cohort D. J Clin Oncol, 33(Suppl), 2015 abstract 8011.
56. 56 Goldberg, S.B., Gettinger, S.N., Mahajan, A., Herbst, R.S., Chiang, A.C., Tsiouris, A.J., et al. Activity and safety of pembrolizumab in patients with metastatic non-small-cell lung cancer with untreated brain metastases. J Clin Oncol, 33(Suppl), 2015 abstract 8035.
57. 57 Vansteenkiste, J., Fehrenbacher, L., Spira, A.I., Mazieres, J., Park, K., Smith, D., et al. Atezolizumab monotherapy vs docetaxel in 2L/3L non-small-cell lung cancer: primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). European Cancer Congress, 2015 abstract LBA14.
58. 58 Spira, A.I., Park, K., Mazières, J., Vansteenkiste, J.F., Rittmeyer, A., Ballinger, M., et al. Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). J Clin Oncol, 33(Suppl), 2015 abstract 8010.
59. 59 Besse, B., Johnson, M., Jänne, P.A., Garassino, M., Eberhardt, W.E.E., Peters, S., et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (NSCLC). European Cancer Congress, 2015 abstract LBA16.
60. 60 Spigel, D.R., Chaft, J.E., Gettinger, S.C., Chao, B.H., Dirix, L.Y., Schmid, P., et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small-cell lung cancer (NSCLC). J Clin Oncol, 33(Suppl), 2015 abstract 8028.
61. 61 Liu, S.V., Powderly, J.D., Camidge, D.R., Ready, N., Heist, R.S., Hodi, F.S., et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol, 33(Suppl), 2015 abstract 8030.
62. 62 Rizvi, N.A., Brahmer, J.R., Ou, S.H.I., Segal, N.H., Khleif, S., Hwu, W.J., et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small-cell lung cancer (NSCLC). J Clin Oncol, 33(Suppl), 2015 abstract 8032.
63. 63 Gulley, J.L., Spigel, D., Kelly, K., Chandler, J.C., Rajan, A., Hassan, R., et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. J Clin Oncol, 33(Suppl), 2015 abstract 8034.
64. 64 Herbst, R.S., Soria, J.C., Kowanetz, M., Fine, G.D., Hamid, O., Gordon, M.S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515 (2014), 563–567.
65. 65 Kerr, K.M., Tsao, M.S., Nicholson, A.G., Yatabe, Y., Wistuba, I.I., Hirsch, F.R., Programmed death-ligand 1 immunohistochemistry in lung cancer: In what state is this art?. J Thorac Oncol 10 (2015), 985–989.
66. 66 Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499 (2013), 214–218.